Bioreponsive polymers

1. A polymer of formula II:

C1[-P-(Bio-{C2-Bio} m -P) n —C1-(Oligo) o -] p   (II)

wherein

(i) each Bio is, independently, one or more biologically active agents, or precursors thereof, tethered to polyamide linker P through hydrolysable covalent bonds;

(ii) each P is a polyamide linker susceptible to hydrolysis by a peptidase enzyme and tethered to said Bio and C1; and

(iii) C1 is a coupling segment linking P to Oligo, wherein C1 is formed from a silicone diol;

(iv) C2 is a polyamide linker susceptible to hydrolysis by a peptidase enzyme linking Bio to Bio;

(v) Oligo is a short length of polymer segment having a molecular weight of less than 5,000 and comprising less than 100 monomeric repeating units; wherein

each of n, o, and p is independently an integer greater than 0; and

m is an integer 0 or 1;

wherein said polyamide linker comprises an amino acid sequence selected from the group consisting of:

β-Ala-gly-ser-gly-arg-pro-arg-gln-ile-thr-ala-ala (SEQ ID NO. 4);

Pro-arg-arg-arg-arg-pro-arg-gln-ile-thr-ala (SEQ ID NO. 6);

β-ala-asp-asp-ile-gly-thr-ser-arg-pro-gln-glu (SEQ ID NO. 8);

Phe-ala-ala-gly-ile-gly-thr-ser-arg-pro-gln (SEQ ID NO. 10);

Gly-gly-gly-gly-gly-ala-leu-leu-glu (SEQ ID NO. 12);

β-ala-gly-lys-pro-ala-leu-phe-phe-arg-leu (SEQ ID NO. 13);

β-ala-ser-leu-ala-ser-pro-pro-thr-ser-leu-val-phe (SEQ ID NO. 15);

Gly-lys-pro-ala-leu-phe-phe-ala-leu (SEQ ID NO. 17); and

β-ala-lys-leu-arg-phe-ser-lys-gln-glu-asp-asp (SEQ ID NO. 19).

2. The polymer of claim 1 , wherein each P is an independent polyamide linker comprising 60 or fewer amino acids.

3. The polymer of claim 1 , wherein said Bio is one or more biologically-active entities selected from the group consisting of carbohydrates, antibiotics, antiproliferative agents, rapamycin macrolides, analgesics, anesthetics, antiangiogenic agents, antithrombotic agents, vasoactive agents, anticoagulants, immunomodulators, cytotoxic agents, antiviral agents, antibodies, neurotransmitters, psychoactive drugs, oligonucleotides, vitamins, lipids, and prodrugs thereof.

4. The polymer of claim 1 , wherein Oligo comprises polyurethane, polyurea, polyamides, polycarbonate, polyester, polylactone, polysilicone, polyethersulfone, polyolefin, polyvinyl derivative, polypeptide, polysaccharide, polysiloxane, polydimethylsiloxane, polyethylene-butylene, polyisobutylene, polybutadiene, polypropylene oxide, polytetramethylene oxide, or polyethylenebutylene segments.

5. A composition comprising the polymer of claim 1 blended with a compatible base polymer.

6. The composition of claim 5 , wherein said base polymer is selected from the group consisting of polyurethanes, polysulfones, polycarbonates, polyesters, polyethylene, polypropylene, polystyrene, polysilicone, poly(acrylonitrile-butadienestyrene), polybutadiene, polyisoprene, polymethylmethacrylate, polyamine, polyvinylacetate, polyacrylonitrile, polyvinyl chloride, polyethylene, terephthalate, cellulose and other polysaccharides.

7. A shaped article comprising the composition of claim 5 .

8. A shaped article comprising the polymer of claim 1 .

9. The shaped article of claim 8 , wherein said shaped article is in the form of an implantable medical device, self-supporting film, or fiber.

10. The shaped article of claim 9 , wherein said article is an implantable medical device selected from the group consisting of a cardiac-assist device, a catheter, a stent, a prosthetic implant, a suture, a cuff, a mesh, a hernia patch, a wound dressing, a bandage, an artificial sphincter, and a drug delivery device.

11. The polymer of claim 1 , wherein each P, independently, comprises an amino acid sequence selected from the group consisting of:

β-Ala-gly-ser-gly-arg-pro-arg-gln-ile-thr-ala-ala (SEQ ID NO. 4);

Pro-arg-arg-arg-arg-pro-arg-gln-ile-thr-ala (SEQ ID NO. 6);

β-ala-asp-asp-ile-gly-thr-ser-arg-pro-gln-glu (SEQ ID NO. 8);

Phe-ala-ala-gly-ile-gly-thr-ser-arg-pro-gln (SEQ ID NO. 10);

Gly-gly-gly-gly-gly-ala-leu-leu-glu (SEQ ID NO. 12);

β-ala-gly-lys-pro-ala-leu-phe-phe-arg-leu (SEQ ID NO. 13); and

Gly-lys-pro-ala-leu-phe-phe-ala-leu (SEQ ID NO. 17).

12. The polymer of claim 1 , wherein said Bio is an antibiotic.

13. The polymer of claim 12 , wherein said Bio is formed from ciprofloxacin.

14. The polymer of claim 1 , wherein Oligo comprises a polyester.

15. The polymer of claim 14 , wherein Oligo comprises poly-caprolactone.

16. The polymer of claim 4 , wherein said polymer comprises a moiety —P-Bio-P—, wherein Bio is ciprofloxacin, a P comprises the sequence β-Ala-gly-ser-gly-arg-pro-arg-gln-ile-thr-ala-ala (SEQ ID NO. 4), and the second P comprises the sequence Pro-arg-arg-arg-arg-pro-arg-aln-ile-thr-ala (SEQ ID NO. 6).

17. The polymer of claim 4 , wherein said polymer comprises a moiety —P-Bio-P—, wherein Bio is ciprofloxacin, a P comprises the sequence β-ala-asp-asp-ile-gly-thr-ser-arg-pro-gln-glu (SEQ ID NO. 8), and the second P comprises the sequence Phe-ala-ala-gly-ile-gly-thr-ser-arg-pro-gln (SEQ ID NO. 10).

18. The polymer of claim 4 , wherein said polymer comprises a moiety —P-Bio-P—, wherein Bio is ciprofloxacin, a P comprises the sequence β-ala-asp-asp-ile-gly-thr-ser-arg-pro-gln-glu (SEQ ID NO. 8), and the second P comprises the sequence Gly-gly-gly-gly-gly-ala-leu-leu-glu (SEQ ID NO. 12).

19. The polymer of claim 4 , wherein said polymer comprises a moiety —P-Bio-P—, wherein Bio is ciprofloxacin, a P comprises the sequence β-ala-gly-lys-pro-ala-leu-phe-phe-arg-leu (SEQ ID NO. 13), and the second P comprises the sequence Gly-lys-pro-ala-leu-phe-phe-ala-leu (SEQ ID NO. 17).